Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function

Daprodustat is a hypoxia‐inducible factor‐prolyl hydroxylase inhibitor in development for treatment of anemia of chronic kidney disease. We evaluated the role of hepatic impairment on daprodustat pharmacokinetics, pharmacodynamics, and tolerability. Participants with mild (Child‐Pugh Class A, score...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahar, Kelly M., Shaddinger, Bonnie C., Ramanjineyulu, Bandi, Andrews, Susan, Caltabiano, Stephen, Lindsay, Alistair C., Cobitz, Alexander R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310628/
https://www.ncbi.nlm.nih.gov/pubmed/35355447
http://dx.doi.org/10.1002/cpdd.1090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310628/
https://www.ncbi.nlm.nih.gov/pubmed/35355447
http://dx.doi.org/10.1002/cpdd.1090

Ejemplares similares